Author response for "Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors"
Antongiulio Faggiano(European Neuroendocrine Tumor Society), Annamaria Colao(Federico II University Hospital), Emanuele Di Simone(Istituti di Ricovero e Cura a Carattere Scientifico), Pasqualino Malandrino(Ospedale Garibaldi), Rossella Mazzilli(Azienda Ospedaliera Sant'Andrea), Elisa Giannetta(Sapienza University of Rome), Marialuisa Appetecchia(Istituti di Ricovero e Cura a Carattere Scientifico), Roberta Modica(University of Naples Federico II), Tiziana Feola(Istituto Neurologico Mediterraneo), Francesco Panzuto(Sapienza University of Rome), Giulia Puliani(National Cancer Institute), Francesco Ferraù(Université Paris-Sud), Antonio Prinzi(Ospedale Garibaldi), Rosa Lauretta(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Rinzivillo(Sapienza University of Rome), Nicolò Panattoni(National Cancer Institute), Flaminia Russo(Sapienza University of Rome), Marco Di Muzio(Sapienza University of Rome), Virginia Zamponi(Sapienza University of Rome), Franz Sesti(Sapienza University of Rome), Ylenia Alessi(University of Messina), Gianfranco Di Iasi(University of Naples Federico II), Pasquale Dolce
Cited by 0
Related Papers
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
|Clinical Endocrinology|2006|830
Guidelines for Acromegaly Management: An Update
|The Journal of Clinical Endocrinology & Metabolism|2009|763
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Complications of Cushing's syndrome: state of the art
|The Lancet Diabetes & Endocrinology|2016|602
Nutritional recommendations for CoVID-19 quarantine
|European Journal of Clinical Nutrition|2020|548